Microbiota-Inducible Innate Immune Siderophore Binding Protein Lipocalin 2 Is Critical for Intestinal Homeostasis

Cellular and Molecular Gastroenterology and Hepatology

Volumn 2, Issue 4, 2016, Pages 482-498.e6

  Singh, Vishal ^a   Yeoh, Beng San ^a   Chassaing, Benoit ^b   Zhang, Benyue ^b   Saha, Piu ^a   Xiao, Xia ^a   Awasthi, Deepika ^c   Shashidharamurthy, Rangaiah ^d   Dikshit, Madhu ^c   Gewirtz, Andrew ^b   Vijay Kumar, Matam ^a,e  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Colitis; Germ Free mice; Gut microbiota; IBD; Innate immunity; MyD88; Neutrophils; NGAL; Siderocalin

Indexed keywords

DEXTRAN SULFATE; INTERLEUKIN 10 RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RNA 16S; SIDEROPHORE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; HOMEOSTASIS; HUMAN; HUMAN CELL; INTESTINE FLORA; IRRITABLE COLON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYROSEQUENCING; T LYMPHOCYTE;

EID: 84975221149     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2016.03.007     Document Type: Article

References (72)

1. Ananthakrishnan A.N. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015, 12:205-217.
2. Morgan X.C., Tickle T.L., Sokol H., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012, 13:R79.
3. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
4. Campbell C.A., Walker-Smith J.A., Hindocha P., et al. Acute phase proteins in chronic inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr 1982, 1:193-200.
5. Janas R.M., Ochocinska A., Snitko R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) in blood in children with inflammatory bowel disease. J Gastroenterol Hepatol 2014, 29:1883-1889.
6. Nielsen B.S., Borregaard N., Bundgaard J.R., et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996, 38:414-420.
7. Vijay-Kumar M., Sanders C.J., Taylor R.T., et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007, 117:3909-3921.
8. Chassaing B., Srinivasan G., Delgado M.A., et al. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One 2012, 7:e44328.
9. Viau A., El Karoui K., Laouari D., et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010, 120:4065-4076.
10. Yang J., Mori K., Li J.Y., et al. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003, 285:F9-F18.
11. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
12. Rodvold J.J., Mahadevan N.R., Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett 2012, 316:132-138.
13. Chakraborty S., Kaur S., Guha S., et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 2012, 1826:129-169.
14. Goetz D.H., Holmes M.A., Borregaard N., et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10:1033-1043.
15. Devireddy L.R., Hart D.O., Goetz D.H., et al. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 2010, 141:1006-1017.
16. Bao G.H., Xu J., Hu F.L., et al. EGCG inhibit chemical reactivity of iron through forming an Ngal-EGCG-iron complex. Biometals 2013, 26:1041-1050.
17. Bao G., Clifton M., Hoette T.M., et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 2010, 6:602-609.
18. Srinivasan G., Aitken J.D., Zhang B., et al. Lipocalin 2 deficiency dysregulates iron homeostasis and exacerbates endotoxin-induced sepsis. J Immunol 2012, 189:1911-1919.
19. Nelson A.L., Ratner A.J., Barasch J., et al. Interleukin-8 secretion in response to aferric enterobactin is potentiated by siderocalin. Infect Immun 2007, 75:3160-3168.
20. Bachman M.A., Miller V.L., Weiser J.N. Mucosal lipocalin 2 has pro-inflammatory and iron-sequestering effects in response to bacterial enterobactin. PLoS Pathog 2009, 5:e1000622.
21. Hu L., Hittelman W., Lu T., et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009, 89:531-548.
22. Tong Z., Wu X., Ovcharenko D., et al. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 2005, 391:441-448.
23. Flo T.H., Smith K.D., Sato S., et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432:917-921.
24. Allred B.E., Rupert P.B., Gauny S.S., et al. Siderocalin-mediated recognition, sensitization, and cellular uptake of actinides. Proc Natl Acad Sci U S A 2015, 112:10342-10347.
25. Guglani L., Gopal R., Rangel-Moreno J., et al. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS One 2012, 7:e50052.
26. Schroll A., Eller K., Feistritzer C., et al. Lipocalin 2 ameliorates granulocyte functionality. Eur J Immunol 2012, 42:3346-3357.
27. Singh V., Yeoh B.S., Xiao X., et al. Interplay between enterobactin, myeloperoxidase and lipocalin 2 regulates E. coli survival in the inflamed gut. Nat Commun 2015, 6:7113.
28. Warszawska J.M., Gawish R., Sharif O., et al. Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. J Clin Invest 2013, 123:3363-3372.
29. Playford R.J., Belo A., Poulsom R., et al. Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology 2006, 131:809-817.
30. de Bruyn M., Arijs I., De Hertogh G., et al. Serum neutrophil gelatinase b-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn's disease. J Crohns Colitis 2015, 9:1079-1087.
31. Vijay-Kumar M., Wu H., Aitken J., et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 2007, 13:856-864.
32. Carlson M., Raab Y., Seveus L., et al. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002, 50:501-506.
33. Oikonomou K.A., Kapsoritakis A.N., Theodoridou C., et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol 2012, 47:519-530.
34. Vijay-Kumar M., Gentsch J.R., Kaiser W.J., et al. Protein kinase R mediates intestinal epithelial gene remodeling in response to double-stranded RNA and live rotavirus. J Immunol 2005, 174:6322-6331.
35. Singh V., Kumar M., Yeoh B.S., et al. Inhibition of interleukin-10 signaling induces microbiota-dependent chronic colitis in apolipoprotein E deficient mice. Inflamm Bowel Dis 2016, 22:841-852.
36. Chassaing B., Aitken J.D., Malleshappa M., et al. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 2014, 104. unit 15.25.
37. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
38. Carvalho F.A., Nalbantoglu I., Ortega-Fernandez S., et al. Interleukin-1beta (IL-1beta) promotes susceptibility of Toll-like receptor 5 (TLR5) deficient mice to colitis. Gut 2012, 61:373-384.
39. Singh V., Yeoh B.S., Carvalho F., et al. Proneness of TLR5 deficient mice to develop colitis is microbiota dependent. Gut Microbes 2015, 6:279-283.
40. Ferrier L., Berard F., Debrauwer L., et al. Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. Am J Pathol 2006, 168:1148-1154.
41. Sanders C.J., Moore D.A., Williams I.R., et al. Both radioresistant and hemopoietic cells promote innate and adaptive immune responses to flagellin. J Immunol 2008, 180:7184-7192.
42. Carvalho F.A., Aitken J.D., Gewirtz A.T., et al. TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage. Mucosal Immunol 2011, 4:102-111.
43. Singh V., Chassaing B., Zhang L., et al. Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient mice. Cell Metab 2015, 22:983-996.
44. Ziegler T.R., Luo M., Estivariz C.F., et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2008, 294:R402-R410.
45. Chinen T., Komai K., Muto G., et al. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun 2011, 2:190.
46. Edgar R.C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010, 26:2460-2461.
47. Ostvik A.E., Granlund A.V., Torp S.H., et al. Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clin Exp Immunol 2013, 173:502-511.
48. Martensson J., Xu S., Bell M., et al. Immunoassays distinguishing between HNL/NGAL released in urine from kidney epithelial cells and neutrophils. Clin Chim Acta 2012, 413:1661-1667.
49. Araki A., Kanai T., Ishikura T., et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005, 40:16-23.
50. Singh B., Su Y.C., Riesbeck K. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol 2010, 78:545-560.
51. Sakwe A.M., Koumangoye R., Goodwin S.J., et al. Fetuin-A ((alpha)2HS-glycoprotein) is a major serum adhesive protein that mediates growth signaling in breast tumor cells. J Biol Chem 2010, 285:41827-41835.
52. Lucke K., Miehlke S., Jacobs E., et al. Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. J Med Microbiol 2006, 55:617-624.
53. Nagalingam N.A., Kao J.Y., Young V.B. Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. Inflamm Bowel Dis 2011, 17:917-926.
54. Hooper L.V., Macpherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 2010, 10:159-169.
55. Hokari R., Kurihara C., Nagata N., et al. Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis. Am J Physiol Gastrointest Liver Physiol 2011, 300:G401-G408.
56. Fournier B.M., Parkos C.A. The role of neutrophils during intestinal inflammation. Mucosal Immunol 2012, 5:354-366.
57. Xu M.J., Feng D., Wu H., et al. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 2015, 61:692-702.
58. Kjeldsen L., Johnsen A.H., Sengelov H., et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425-10432.
59. Hammond M.E., Lapointe G.R., Feucht P.H., et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 1995, 155:1428-1433.
60. Weber D.A., Sumagin R., McCall I.C., et al. Neutrophil-derived JAML inhibits repair of intestinal epithelial injury during acute inflammation. Mucosal Immunol 2014, 7:1221-1232.
61. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
62. Miao Q., Ku A.T., Nishino Y., et al. Tcf3 promotes cell migration and wound repair through regulation of lipocalin 2. Nat Commun 2014, 5:4088.
63. Eller K., Schroll A., Banas M., et al. Lipocalin-2 expressed in innate immune cells is an endogenous inhibitor of inflammation in murine nephrotoxic serum nephritis. PLoS One 2013, 8:e67693.
64. Li B., Alli R., Vogel P., et al. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol 2014, 7:869-878.
65. Naude P.J., Nyakas C., Eiden L.E., et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer's disease. FASEB J 2012, 26:2811-2823.
66. Holden V.I., Lenio S., Kuick R., et al. Bacterial siderophores that evade or overwhelm lipocalin 2 induce hypoxia inducible factor 1alpha and proinflammatory cytokine secretion in cultured respiratory epithelial cells. Infect Immun 2014, 82:3826-3836.
67. Kundu P., Ling T.W., Korecka A., et al. Absence of intestinal PPARgamma aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway. PLoS Pathog 2014, 10:e1003887.
68. Frank D.N., St Amand A.L., Feldman R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 104:13780-13785.
69. Shin N.R., Whon T.W., Bae J.W. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 2015, 33:496-503.
70. Winter S.E., Winter M.G., Xavier M.N., et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 2013, 339:708-711.
71. Carvalho F.A., Koren O., Goodrich J.K., et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 2012, 12:139-152.
72. Stallhofer J., Friedrich M., Konrad-Zerna A., et al. Lipocalin-2 is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-alpha and modulated by IL23R genotype status. Inflamm Bowel Dis 2015, 21:2327-2340.